Table 4.
Cost-effectiveness analysis for the 1-year and 2-year periods
| Cost (€) | Effectiveness (HbA1c) | Incremental cost | Incremental HbA1c decrease | ICER | |
|---|---|---|---|---|---|
| 1-year cost, effectiveness and ICER | |||||
| CG | 13,069 [11,700; 15,137] | 7.67 [7.57; 7.75] | – | – | – |
| TMG | 11,735 [10,337; 13,641] | 7.50 [7.41; 7.58] | − 1334 | 0.17 | − 7847 |
| 2-year cost, effectiveness and ICER | |||||
| CG | 26,487 [24,132; 29,817] | 7.73 [7.65; 7.83] | – | – | – |
| TMG | 23,343 [21,007; 26,533] | 7.59 [7.50; 7.68] | − 3144 | 0.14 | − 22,457 |
CG control group, TMG telemonitoring group, ICER incremental cost-effectiveness ratio